Paper Details

  1. Home
  2. Paper Details

Deferiprone for the treatment of transfusional iron overload in thalassemia.

Author: BelmontAmi, KwiatkowskiJanet L

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This article reviews the efficacy, adverse effects, and use of deferiprone, an oral iron chelator used to treat transfusional iron overload.
Paper Details　
Original Abstract of the Article :
Transfusional iron overload can lead to hepatic fibrosis, arrhythmias and congestive heart failure and a number of endocrinopathies. Deferiprone is an oral iron chelator approved for use in the United States as a second line agent for the treatment of transfusional iron overload in patients with tha...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/17474086.2017.1318052

データ提供：米国国立医学図書館（NLM）

Deferiprone: A New Weapon in the Battle Against Iron Overload

This review examines the use of deferiprone, an oral iron chelator, in the treatment of transfusional iron overload in patients with thalassemia. Thalassemia is a genetic blood disorder that requires frequent blood transfusions, which can lead to iron overload and potentially serious health complications. The review discusses the efficacy of deferiprone in chelating iron, preventing complications, and its adverse effect profile.

Deferiprone: A Promising Treatment for Iron Overload in Thalassemia

The research suggests that deferiprone is a valuable treatment option for iron overload in thalassemia patients. Its effectiveness in chelating iron and reducing the risk of complications, such as heart problems and liver damage, makes it an important tool in managing this complex genetic disorder.

Understanding Iron Overload in Thalassemia

Thalassemia is a genetic blood disorder that affects the production of hemoglobin, a protein that carries oxygen in red blood cells. Patients with thalassemia often require frequent blood transfusions to compensate for low red blood cell levels. These transfusions can lead to iron overload, which can damage vital organs.

Dr.Camel's Conclusion

This review highlights the importance of deferiprone in the management of transfusional iron overload in patients with thalassemia. Its effectiveness in chelating iron and reducing the risk of complications underscores the need for access to this vital medication.
Date :
  1. Date Completed 2017-06-09
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

28448199

DOI: Digital Object Identifier

10.1080/17474086.2017.1318052

Related Literature

Article Analysis
・Side Effects of deferiprone
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.